SMS Pharmaceuticals Limited — Updates, 23-05-2026: General Updates

SMS Pharma's FY26 revenue grew 13% to ₹887 Cr, with PAT soaring 47% to ₹102 Cr and EBITDA margin at 19%. This strong performance is driven by backward integration and a high-value product mix. A ₹280 Cr Capex program is on track. Board announced a ₹0.40/share dividend.